Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Top Cited Papers
- 16 August 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 390 (10105), 1853-1862
- https://doi.org/10.1016/s0140-6736(17)31601-x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaJournal of Clinical Oncology, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaThe New England Journal of Medicine, 2015
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsCancer, 2014
- Immunomodulatory therapy for melanoma: Ipilimumab and beyondClinics in Dermatology, 2013
- Ipilimumab in advanced melanomaMelanoma Research, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibThe New England Journal of Medicine, 2012
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnnals of Oncology, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- A sharper Bonferroni procedure for multiple tests of significanceBiometrika, 1988